Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL

Zhou, Yanfang; Li, Yun; Li, Xiangnan; Jiang, Minjun

doi:10.1155/2017/2512536

Cited by 13 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It demonstrated that PCA3 was a more suitable biomarker for PCA diagnosis. Yet our AUC data was slightly lower than in some other studies and did not illustrate a significant benefit of PCA3 test [12] , [27] . This decrease of statistical power may be explained by the restricted proportion of negative biopsy.…”

Section: Discussioncontrasting

confidence: 91%

Clinical Significance of Peripheral Blood PCA3 Gene Expression in Early Diagnosis of Prostate Cancer

Chen

Zhao

et al. 2018

Translational Oncology

View full text Add to dashboard Cite

Prostate cancer antigen 3 (PCA3) is one of the most promising genes currently investigated as a specific tumor biomarker for the diagnosis of prostate cancer. The purpose of this study was to investigate PCA3 gene expression in peripheral blood of prostate cancer (PCa) and benign prostate hyperplasia (BPH), and further to assess its clinical significance. We determined the copies of PCA3 mRNA in peripheral blood of PCa and BPH from 115 samples (PCa, n = 78; BPH, n = 37) using a quantitative reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) with TaqMan assay. The sensitivity and specificity of PCA3 for the diagnosis of prostate cancer was compared with that of prostate-specific antigen (PSA) by receiver operating characteristic (ROC) curve analysis. To evaluate the association between PCA mRNA and disease progression, we analyzed PCA3 levels in connection with Gleason score and TNM stage of PCa. The clinical data revealed that expression of PCA3 gene was significantly higher in PCa than in BPH. Moreover, PCA3 mRNA was significantly higher in PCa patients with a Gleason score ≥8 than in those with a Gleason score ≤7 (P < .01). The results showed that the area under the curve (AUC) was 0.790, 0.606, and 0.620 for the copy number of PCA3, PSA level, and significantly free PSA (fPSA) level, respectively. Increased PCA3 in peripheral blood is correlated with PCa, and the detection of PCA3 may significantly reduce adverse screening outcomes. PCA3 gene expression in peripheral blood had a promising clinical application in the early diagnosis of PCa.

show abstract

Section: Discussioncontrasting

confidence: 91%

Clinical Significance of Peripheral Blood PCA3 Gene Expression in Early Diagnosis of Prostate Cancer

Chen

Zhao

et al. 2018

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…Multiparametric MRI has recently been established in our hospital and we also aim to implement it in the prospective validation of our models. In particular, the value of EPCAM and PSGR urinary transcripts deserves further analysis as they have so far been reported only in few studies [ 17 , 21 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy

et al. 2020

View full text Add to dashboard Cite

The main advantage of urinary biomarkers is their noninvasive character and the ability to detect multifocal prostate cancer (CaP). We have previously implemented a quadruplex assay of urinary markers into clinical practice (PCA3, AMACR, TRPM8 and MSMB with KLK3 normalization). In this study, we aimed to validate it in a larger cohort with serum PSA 2.5–10 ng/mL and test other selected transcripts and clinical parameters, including the percentage of free prostate-specific antigen (PSA) (% free PSA) and inflammation. In the main cohort of 299 men, we tested the quadruplex transcripts. In a subset of 146 men, we analyzed additional transcripts (CD45, EPCAM, EZH2, Ki67, PA2G4, PSGR, RHOA and TBP). After a prostate massage, the urine was collected, RNA isolated from a cell sediment and qRT-PCR performed. Ct values of KLK3 (i.e., PSA) were strongly correlated with Ct values of other genes which play a role in CaP (i.e., PCA3, AMACR, TRPM8, MSMB and PSGR). AMACR, PCA3, TRPM8 and EZH2 mRNA expression, as well as % free PSA, were significantly different for BPH and CaP. The best combined model (% free PSA plus PCA3 and AMACR) achieved an AUC of 0.728 in the main cohort. In the subset of patients, the best AUC 0.753 was achieved for the combination of PCA3, % free PSA, EPCAM and PSGR. PCA3 mRNA was increased in patients with inflammation, however, this did not affect the stratification of patients indicated for prostate biopsy. In conclusion, the percentage of free PSA and urinary markers contribute to a more accurate indication for prostate biopsy.

show abstract

“…The recent studies revealed a potential diagnostic role of some metabolites that may improve cancer detection rate and prognostication such as sarcosine, oleate, kynurenine or cholesteryl, as well as the expression of metabolic enzymes involved in specific pathways (Lucarelli et al, 2013;Lucarelli et al, 2012). In addition, the combined diagnostic value of urinary biomarker panels such as MALAT-1, PCA3, PSGR and PSMA was also proved to be impressive in patients with PSA levels in grey zone, particularly when selecting prostate cancer-suspected patients for biopsy in clinical practice (Zhou, Li, Li, & Jiang, 2017). Roberts et al (2015) suggested that PHI and PCA3 demonstrated higher predictive diagnostic accuracy compared with more traditional indicators used in early detection of PCa.…”

Section: Discussionmentioning

confidence: 99%

Can the combination of biparametric magnetic resonance imaging and PSA‐related indicators predict the prostate biopsy outcome?

et al. 2020

View full text Add to dashboard Cite

To assess the value of biparametric magnetic resonance imaging (bpMRI) for detecting and ruling out prostate cancer in patients with elevated prostate-specific antigen (PSA). The basic information and bpMRI images of enrolled patients who took transperineal template saturate biopsy were retrospectively collected for analysis. Based on our results, we found that free/total PSA, and PI-RADS score were independent risk factors of PCa (p < .05), the PSA density, PI-RADS score were the independent risk factors of csPCa (p < .05). PI-RADS score threshold of 3 could achieve the highest Yonder index for predicting PCa, and PI-RADS score threshold of 4 could achieve the highest Yonder index for predicting csPCa. Therefore, we draw a conclusion that PI-RADSv2 score-based bpMRI could diminish the unnecessary prostate biopsies in patients with elevated PSA when combined with other PSA-related indicators. K E Y W O R D S bpMRI, PI-RADS, prostate cancer, prostate-specific antigen How to cite this article: Zhu J, Liang Z, Song Y, et al. Can the combination of biparametric magnetic resonance imaging and PSA-related indicators predict the prostate biopsy outcome?.

show abstract

Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL

Cited by 13 publications

References 21 publications

Clinical Significance of Peripheral Blood PCA3 Gene Expression in Early Diagnosis of Prostate Cancer

Clinical Significance of Peripheral Blood PCA3 Gene Expression in Early Diagnosis of Prostate Cancer

The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy

Can the combination of biparametric magnetic resonance imaging and PSA‐related indicators predict the prostate biopsy outcome?

Contact Info

Product

Resources

About